Facing strong opposition from a rare alliance of the pharma and tech industries as well as past agency leaders, the U.S. Patent and Trademark Office (USPTO) has withdrawn a proposed new rule directed at Terminal Disclaimer...more
12/10/2024
/ Corporate Counsel ,
Life Sciences ,
Obviousness-Type Double Patenting (ODP) ,
Patent Applications ,
Patent Portfolios ,
Patents ,
Pharmaceutical Industry ,
Proposed Rules ,
Technology ,
Terminal Disclaimer ,
USPTO
When it comes to product development, the management of third-party intellectual property (IP) to ensure freedom to operate is of paramount importance. Drug development is no different. Imagine investing years of research,...more
The U.S. Supreme Court has agreed to hear a case that is extremely significant for companies that operate in the biotechnology, pharmaceutical, and chemical sectors. At issue in Amgen v. Sanofi is a determination of the...more